Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Boston Scientific Corporation announced that Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, will retire effective December 1, 2025 and remain as a senior advisor through February 27, 2026. During the advisory period he will receive his current base salary of $705,000, prorated to the Retirement Date. The company expects to enter a Retirement Agreement providing payments and benefits materially consistent with its Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and related equity awards.
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported multiple transactions on 09/02/2025 effected under a pre-established Rule 10b5-1 trading plan adopted February 27, 2025. The report shows 50,000 shares acquired at a price of $26.15 (code M) and two dispositions totaling 50,000 shares sold in multiple trades at weighted average prices of $104.886 and $105.8486. After these transactions, the reporting person beneficially owned 178,342 shares directly, with an additional 5,234 shares held indirectly by his child which he disclaims beneficial ownership of. The filing includes an option related entry reflecting a 50,000-share option with the same $26.15 figure and references vesting in four equal annual installments beginning December 1, 2018.
The form is signed by an attorney-in-fact on behalf of the reporting person and discloses the reporting person will provide detailed per-price sale breakdowns upon request by the SEC or others.
Boston Scientific Corp. Form 144 notice reports a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $5,271,415.00, with an approximate sale date of 09/02/2025. The filing states these 50,000 shares were acquired the same day by stock option exercise and paid for in cash.
The filing also discloses prior sales by the same person, JOSEPH M FITZGERALD, totaling 156,372 shares across three transactions on 06/04/2025, 07/01/2025, and 08/01/2025, generating gross proceeds of $16,985,599.64 combined. The notice includes the seller's representation that no undisclosed material adverse information is known.